Dr. Reed is an experienced Pharmaceutical Executive, having lead multiple successful projects including 10 INDs and 7 NDA/sNDA submissions. She has been a key contributor to teams that have delivered five pre-clinical candidates one of which advanced to market for the treatment of cancer (dacomitinib) Vizimpro, and one that advanced to phase I, for diabetes. She is currently the CEO of Diapin Therapeutics, Inc. She has advanced multiple discovery projects in oncology, CNS, and metabolic disease groups, providing leadership and scientific oversight to teams of cross functional scientists. Jessica is highly engaged, with excellent leadership, project management, communication, problem solving, organizational and analytical skills. She has over 25 years of experience in the pharmaceutical industry with a proven record of accomplishment in discovery, nonclinical and clinical research projects.